Du är här

2015-10-14

Curetis AG: Curetis Announces Intention to Launch Its Initial Public Offering and Listing on Euronext Amsterdam and Euronext Brussels

Curetis AG / Curetis Announces Intention to Launch Its Initial Public Offering
and Listing onEuronext Amsterdam and Euronext Brussels . Processed and
transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely
responsible for the content of this announcement.
NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR
IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH
AFRICA OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS
ANNOUNCEMENT.

Holzgerlingen, Germany, October 14, 2015
-- Curetis AG ("Curetis
"), a developer of next-level molecular diagnostic solutions, today announces
its intention to launch an Initial Public Offering (the "IPO
" or the "Offering
") of new ordinary shares in the capital of a newly incorporated Dutch holding
company - Curetis N.V.[1] - and the listing of all ordinary shares on
Euronext in Amsterdam and Euronext in Brussels.

Company Highlights

Commercial-stage molecular diagnostics for the simple, accurate and rapid
detection of infectious diseases and antibiotic resistance in severely ill,
hospitalized patients at the point of need.

* With its Unyvero Platform, Curetis has developed a walk-away solution that
detects a broad range of different microorganisms and antibiotic resistance
markers in a single test from a wide variety of native sample materials
within four to five hours. In contrast, the diagnosis of infectious
diseases in a hospital setting today is still largely carried out through
traditional microbiology culture based tests, a labor-intensive and
time-consuming process typically delivering results only after 24 to 72
hours or even weeks.
* The Unyvero Platform allows clinicians to make early adjustments to a more
specific treatment of the patient, saving significant time and cost, in
particular by reducing the time of the patient's hospital stay. Moreover,
informed therapy decisions may prevent or decrease the risk of antibiotic
resistance development, a major challenge in healthcare worldwide.

Versatile, robust CE-marked Unyvero Platform

* The CE-IVD marked Unyvero Platform is designed as a robust,
infrastructure-independent, near-patient solution that can be operated
automatically with minimal hands-on time and by non-laboratory staff. It
has been validated in over 30 completed clinical studies and endorsed by
key opinion leaders.
* It consists of instruments (L4 Lysator, C8 Cockpit, and A50 Analyzer),
proprietary software, and disposable Application Cartridges specifically
designed for various indication areas.
* It deals with a large variety of sample types and covers more
microorganisms and resistance markers than competing platforms.

High-value products addressing significant unmet medical need

* The P55 Application Cartridge addresses severe pneumonia infections and
detects 21 pneumonia-causing pathogens and 19 clinically relevant
resistance markers against antimicrobials.
* The i60 ITI Application Cartridge detects 61 microorganisms and 19
antibiotic resistance markers relevant for eight different clinical
indications: prosthetic joint and other implant infections, diabetic foot
ulcers, surgical site infections, catheter-associated infections, deep skin
and tissue infections, cardiology-related infections, and burn wounds.
* Curetis' pipeline of product candidates includes Application Cartridges for
blood culture testing and intra-abdominal/gastrointestinal tract infections
and a sepsis host response Application Cartridge

Focus on global commercial expansion

* Curetis' Unyvero Systems and Application Cartridges are commercialized in
Europe and certain other markets that accept CE-marking (i.e. Kuwait,
Qatar, Russia and United Arab Emirates).
* Curetis also intends to further expand internationally as seen by the
recent signing of distribution agreements with Acumen for certain ASEAN
markets (initially Indonesia, Malaysia, Singapore and Thailand) and Beijing
CLEAR Biotech for Greater China (consisting of China, Taiwan and Hong
Kong).
* In the U.S., Curetis is currently running a prospective multi-center
clinical trial aimed at achieving FDA clearance and a subsequent market
launch in 2017.

Strong management team and investor base

* Curetis' management team combines decades of operational and commercial
experience in the MDx industry.
* Curetis is backed by renowned investors, including Aeris Capital, LSP Life
Sciences Partners, Forbion, HBM Partners, BioMed Partners, Roche Venture
Fund, QIAGEN, CD-Venture and KfW.

Further company highlights

* Curetis controls all key aspects of its value chain;
* manufactures all Application Cartridges in-house, with its highly automated
cleanroom assembly line;
* believes that its Unyvero Platform has the potential for menu expansion
into other areas, such as oncology, companion diagnostics, transplant
medicine and veterinary applications.

"Timely and precise information about pathogens and resistance markers is key
in combating life-threatening infections", said Oliver Schacht, PhD, CEO of
Curetis. "We are providing doctors with relevant information so that they can
make informed treatment decisions within hours. We believe that this leads to
better patient outcomes, shorter hospital stays, and decreased hospital
costs. In addition, adequate antibiotic therapy decisions help to combat the
spread of antibiotic resistance, a significant and increasing problem
throughout the world."

"Curetis has developed a strong pipeline of high-value products addressing a
significant unmet medical need in the infectious diseases space," said Frank
Mühlenbeck, PhD, Chairman of the Supervisory Board of Curetis. "With its
product pipeline of highly multiplexed molecular diagnostics solutions, the
company is well positioned in the fast growing molecular diagnostics market."

The Offering and Listing

The intended Offering is expected to consist of a primary offering of newly
issued ordinary shares in the capital of Curetis N.V. (the "Shares
") through (i) a public offering to retail and institutional investors in
Germany and (ii) a private placement to certain institutional and other
eligible investors in various other jurisdictions.

Certain of Curetis' current shareholders have indicated their intention to
subscribe for Shares offered in the Offering for an aggregate amount of about
€15 million.

Curetis intends to use the net proceeds of the Offering:

* to build a commercial marketing, sales and support presence in the US in
order to directly commercialize the Unyvero System and Application
Cartridges following anticipated FDA clearance;
* to accelerate the R&D pipeline of its Unyvero Application Cartridges for
European, US and other markets, including clinical trials and regulatory
approvals;
* for expanding and strengthening its European commercial presence in markets
where it sells the Unyvero Platform directly to end customers;
* for manufacturing capacity expansion and general corporate purposes.

Curetis intends to have all Shares admitted to listing and trading on Euronext
in Amsterdam, a regulated market of Euronext Amsterdam N.V., as well as on
Euronext in Brussels, a regulated market of Euronext Brussels N.V./S.A. The
Offering and listing, and their timing, are subject to market and other
conditions.

RBC Capital Markets is acting as Sole Global Coordinator for the Offering and
RBC Capital Markets and Bank Degroof Petercam N.V./S.A. together are acting
as Joint Bookrunners for the Offering. ICF Bank AG is acting as Joint Lead
Manager for the Offering.

For further information, please visit
www.unyvero.com
.

About Curetis AG

Founded in 2007, Curetis AG is a molecular diagnostics company which focuses
on the development and commercialization of reliable, fast and cost-effective
products for diagnosing severe infectious diseases. The diagnostic solutions
of Curetis AG enable rapid multi-parameter pathogen and antibiotic resistance
marker detection in only a few hours, a process that today can take up to
days or even weeks with other techniques.

To date, Curetis has raised total funds of over EUR 63.5 million (>US$ 70
million). The company is based in Holzgerlingen near Stuttgart, Germany.
Curetis has signed collaboration agreements with Heraeus Medical and Cempra
Inc. as well as several international distribution agreements covering many
countries across Europe, the Middle East and Asia.

For further information, please visit
www.curetis.com
.

Contact

Curetis AG
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com

www.curetis.com-
www.unyvero.com

Media&Investor Inquiries

akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com

Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68

Important legal information

These materials are for informational purposes only and are not intended to
constitute, and should not be construed as, an offer to sell or subscribe
for, or the announcement of a forthcoming offer to sell or subscribe for, or
a solicitation of any offer to buy or subscribe for, or the announcement of a
forthcoming solicitation of any offer to buy or subscribe for, ordinary
Shares in the share capital of Curetis N.V. (the "Company
") in the United States, Australia, Canada, Japan, South Africa or in any
other jurisdiction to whom or in which such offer or solicitation is unlawful
and the distribution of this communication in jurisdictions may be similarly
restricted. Persons into whose possession this communication comes should
inform themselves about and observe any such restrictions. Any failure to
comply with these restrictions may constitute a violation of the security
laws of any such jurisdiction.

The Shares have not been and will not be registered under the U.S. Securities
Act of 1933, as amended (the "Securities Act
") and may not be offered or sold within the United States absent registration
or an exemption from the registration requirements under the Securities Act.
The Company does not intend to register any portion of the offering in the
United States or to conduct a public offering of Shares in the United States.
The securities referred to herein may not be offered or sold in Australia,
Canada, Japan, South Africa or to, or for the account or benefit of, any
national, resident or citizen of Australia, Canada, Japan or South Africa.

The Company has not authorised any offer to the public of Shares in any Member
State of the European Economic Area, except in the Federal Republic of

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.